The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Amodiaquine analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Amodiaquine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]
[Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Amodiaquine results in increased expression of BAX protein
Amodiaquine results in decreased expression of BCL2 protein [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein
CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]; CTLA4 protein affects the reaction [PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]]
Amodiaquine results in increased activity of CYP1A1 protein CYP1A1 protein results in increased metabolism of Amodiaquine [CYP1A1 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine CYP1A1 protein results in decreased susceptibility to Amodiaquine
Amodiaquine results in decreased activity of CYP1A2 protein CYP1A2 protein results in increased metabolism of Amodiaquine [CYP1A2 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine; [Gemfibrozil results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Amodiaquine; [Trimethoprim results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Amodiaquine
CYP1B1 protein results in decreased susceptibility to Amodiaquine [CYP1B1 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine
CYP2A6 protein results in increased metabolism of Amodiaquine [CYP2A6 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine
CYP2B6 protein results in increased metabolism of Amodiaquine [CYP2B6 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine
Amodiaquine results in decreased activity of CYP2C19 protein [CYP2C19 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine
[5-bromotryptamine analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; [5-chlorotryptamine analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; [5-fluorotryptamine analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased abundance of and results in increased secretion of desethylamodiaquine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of amodiaquine quinoneimine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of desethylamodiaquine; [CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein; [CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein; [CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein; [Gemfibrozil co-treated with Amodiaquine] results in decreased activity of CYP2C8 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; [Tryptamines analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; Felodipine inhibits the reaction [CYP2C8 protein results in increased metabolism of Amodiaquine]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] CYP2C8 protein affects the metabolism of Amodiaquine
[CYP2D6 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine; [CYP2D6 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of amodiaquine quinoneimine
CYP3A4 protein results in increased metabolism of Amodiaquine CYP3A4 protein results in increased susceptibility to Amodiaquine [CYP3A4 protein results in increased metabolism of Amodiaquine] which results in increased abundance of and results in increased secretion of desethylamodiaquine; [CYP3A4 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of amodiaquine quinoneimine; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]
CYP3A7 protein results in increased metabolism of Amodiaquine [CYP3A7 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine
[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; [PDCD1 protein co-treated with LAG3 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; [PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]; CTLA4 protein affects the reaction [PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]]; PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]
[CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein
[CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein
[CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein
Amodiaquine results in decreased expression of MCL1 protein [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein
[PDCD1 protein co-treated with LAG3 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; [PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]; CTLA4 protein affects the reaction [PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]]; PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]
[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Berberine inhibits the reaction [acetamiprid results in increased activity of ACHE protein] Berberine results in decreased activity of ACHE protein
Berberine results in decreased expression of ACTA2 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA]
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA]
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of BAX mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein]
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein]
Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BECN1 mRNA] Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein]
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3 protein Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein] Berberine results in increased expression of BNIP3 protein
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine results in increased expression of BNIP3L protein
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA]
[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP3 protein] Berberine increases activity of CASP3 protein in colon epithelial cells Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 mRNA]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of CASP3 mRNA] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA
Berberine results in increased cleavage of CASP9 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP9 protein] [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [acetamiprid results in decreased activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of CAT protein]
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA]
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein]
15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein]
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA; Berberine results in decreased expression of CEBPA protein
Berberine results in increased expression of CEBPB mRNA Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA]
Berberine results in increased expression of COL1A1 mRNA Berberine inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA]
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein]
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]
Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein]
Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of CXCL8 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] Berberine results in increased expression of CYP2B10 mRNA
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]
[Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein
Berberine results in decreased expression of FABP4 mRNA Berberine results in increased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA]
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of FN1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein
Berberine results in increased expression of FUNDC1 protein [Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein]
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein]
Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of GSR protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein]
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form]
Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein]
Berberine results in increased expression of HMOX1 protein Berberine results in increased expression of HMOX1 mRNA; Berberine results in increased expression of HMOX1 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of HMOX1 protein] Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein]
[Chloroquine co-treated with Berberine] results in decreased expression of IGF2BP3 protein; Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]; Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein] Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein]
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA; Berberine inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein] Berberine results in increased expression of IL10 mRNA
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA]
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL6 protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of LINC00943 mRNA]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]
[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine results in increased localization of MAP1LC3B protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of MAP1LC3B mRNA]
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA]
[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of MIR142 mRNA]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]
Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR mRNA]; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR protein]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein]
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]
Berberine results in increased expression of NFE2L2 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of NFE2L2 protein] Berberine results in increased activity of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein]
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein]
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA] Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein]
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein]
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARA protein]
Berberine results in increased activity of PPARD protein Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARD protein] Berberine results in increased expression of PPARD mRNA; Berberine results in increased expression of PPARD protein
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in decreased expression of PPARG protein] Berberine results in decreased expression of PPARG mRNA; Berberine results in decreased expression of PPARG protein PPARG mRNA results in increased susceptibility to Berberine 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] Berberine results in increased expression of PPARG mRNA
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA]
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA]
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein]
Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 mRNA]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 protein]
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of SOD1 protein]
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [acetamiprid results in decreased expression of SOD2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA]
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein]
Berberine results in increased expression of SQSTM1 protein [Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of STAT3 mRNA]
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of TGFB1 mRNA] Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Dietary Fats results in increased secretion of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of TNF protein]
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]
entacapone results in decreased activity of COMT protein entacapone binds to COMT protein [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; entacapone inhibits the reaction [COMT protein results in increased methylation of Levodopa]
[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MMP9 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MSR1 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA
Ethylmaleimide affects the activity of ABCC1 protein Ethylmaleimide inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]
isocitric acid inhibits the reaction [Ethylmaleimide results in decreased activity of IDH1 protein]; NADP promotes the reaction [Ethylmaleimide results in decreased activity of IDH1 protein]
Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 protein]
Ethylmaleimide results in increased activity of SLC12A5 protein Ethylmaleimide inhibits the reaction [SLC12A5 protein results in increased import of Thallium]
Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 protein]; Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 protein]
Ethylmaleimide inhibits the reaction [SUMO2 protein binds to SENP1 protein]; Ethylmaleimide inhibits the reaction [SUMO2 protein binds to SENP6 protein]
Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 protein]
Ethylmaleimide results in decreased activity of VKORC1 protein Dithiothreitol promotes the reaction [Ethylmaleimide results in decreased activity of VKORC1 protein]
ABCC11 mRNA results in decreased susceptibility to Pemetrexed; ABCC11 protein results in decreased susceptibility to Pemetrexed ABCC11 gene SNP affects the susceptibility to Pemetrexed
Pemetrexed results in increased expression of BBC3 protein xanthohumol promotes the reaction [Pemetrexed results in increased expression of BBC3 protein]
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of BCL2 protein
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CXCL8 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CXCL8 protein
Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein] Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein
Pemetrexed results in increased expression of FAS protein TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein KRAS gene mutant form results in increased susceptibility to Pemetrexed
Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate] SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed
Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate] Pemetrexed results in increased activity of SLC46A1 protein SLC46A1 protein results in increased susceptibility to Pemetrexed
Pemetrexed results in decreased activity of TYMS protein TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein] TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed
AHR protein results in increased abundance of S-Adenosylhomocysteine PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine]
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]
S-Adenosylhomocysteine results in increased expression of APP protein S-Adenosylhomocysteine results in decreased methylation of APP promoter Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]; S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein
S-Adenosylhomocysteine results in decreased activity of DNMT1 protein S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter]
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]
[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]
S-Adenosylhomocysteine results in increased expression of MMP2 mRNA; S-Adenosylhomocysteine results in increased expression of MMP2 protein S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter] U 0126 inhibits the reaction [S-Adenosylhomocysteine results in increased expression of MMP2 protein]
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]; S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter] S-Adenosylhomocysteine results in decreased expression of OGG1 mRNA; S-Adenosylhomocysteine results in decreased expression of OGG1 protein
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] S-Adenosylhomocysteine results in increased expression of PSEN1 protein
tolcapone results in decreased activity of COMT protein [tolcapone results in decreased activity of COMT protein] inhibits the reaction [Levodopa results in increased abundance of Homocysteine]; [tolcapone results in decreased activity of COMT protein] inhibits the reaction [Levodopa results in increased abundance of S-Adenosylmethionine]; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Homovanillic Acid; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of 3,4-Dihydroxyphenylacetic Acid; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Epinephrine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Levodopa; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Norepinephrine; tolcapone inhibits the reaction [COMT protein results in increased methylation of Levodopa] [tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine]; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Homovanillic Acid; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of 3,4-Dihydroxyphenylacetic Acid; tolcapone inhibits the reaction [[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine] COMT protein results in increased methylation of tolcapone tolcapone binds to COMT protein
tolcapone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Tolcapone results in decreased activity of CYP1A1 protein
tolcapone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] tolcapone results in increased expression of CYP1A2 mRNA
CA 074 methyl ester inhibits the reaction [Trifluridine results in increased cleavage of CASP3 protein]; Trifluridine results in increased cleavage of and results in increased activity of CASP3 protein
Trifluridine results in increased cleavage of CTSB protein CA 074 methyl ester inhibits the reaction [Trifluridine results in increased cleavage of CTSB protein]
Trifluridine results in increased activity of NR1I2 protein [Trifluridine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
Trifluridine inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]
browse the term
